Metabolic Disorders Disease & Epidemiology Overview 2018 Featuring Pfizer, Alnylam, Ionis/Akcea, Takeda, Janssen and Genmab & GSK - ResearchAndMarkets.com

December 18, 2018

DUBLIN--(BUSINESS WIRE)--Dec 18, 2018--The “Metabolic Disorders - Disease & Epidemiology Overview” report from Decision Resources Group has been added to ResearchAndMarkets.com’s offering.

The Metabolic Disorders Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 10 indications in the Metabolic Disorders therapy area:

Acromegaly, Amyloidosis, Dyslipidemia, Gout, Non-alcoholic Steatohepatitis, Obesity/Overweight, Osteoporosis, Primary Biliary Cholangitis, Type 1 Diabetes and Type 2 Diabetes Disease. This report provides a disease market overview for each indication and global epidemiology overviews for each indication.

The disease market overviews include information such as market size forecasts, prevailing treatment trend analysis and predictions, key areas of unmet need, current and emerging therapies, physician (KOL) insights, clinical pipeline analysis, and more, for each indication. The global epidemiology overviews provide insights including global diagnosed prevalence, diagnosed prevalence by region, 10-year diagnosed prevalence growth forecast, relative sizes of the factors contributing to the trend in prevalent cases, and more, for each indication.

Key Topics Covered:

About the Analyst About the analyst’s Epidemiology Disease Landscape and Insight Overview Epidemiology Overview

Companies Mentioned

Pfizer Alnylam Ionis/Akcea Takeda Janssen and Genmab GSK

For more information about this report visit https://www.researchandmarkets.com/research/n92dn3/metabolic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181218005302/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/18/2018 04:06 AM/DISC: 12/18/2018 04:06 AM


Update hourly